Status:
ACTIVE_NOT_RECRUITING
Translational Assessment of Vitiligo According to Body Locations
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Vitiligo
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Vitiligo affects 0.5 to 2% of worldwide population and has a demonstrated impact on the quality of life. Optimal treatment of vitiligo requires to target the auto-immune inflammatory response (to hal...
Eligibility Criteria
Inclusion
- Men and women with non-segmental vitiligo for the vitiligo group and men and women without any auto-immune disorder for the control group
- ≥ 18 and \<70 years
- For women of child-bearing age, a urine pregnancy test (βHCG in urines) will be performed.
- Affiliation to a social security system
- Signed informed consent
Exclusion
- Pregnant women
- Segmental or mixed vitiligo
- Vitiligo with less than 2 years duration
- Skin auto-immune or inflammatory skin disorders other than vitiligo (ie. active atopic dermatitis, psoriasis, lichen planus…)
- Exposure to sun (with intent to tan or repigment the skin) or artificial UV (UV cabins, lamps or lasers) during the month before inclusion
- Concomitant use of topical or systemic immunosuppressive medication or steroids
- Contra-indication to xylocaine with 2 % adrenalin
- Pregnant or breast-feeding women
- Vulnerable people: minors, adult under guardianship or deprived of freedom, adult under curatorship
- Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation
Key Trial Info
Start Date :
June 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 2 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06068218
Start Date
June 18 2024
End Date
April 2 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-maritimes, France, 06200